Company / Operating Margin
Gain Therapeutics, Inc. Operating Margin History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-40328.3%
FY2024
5-year range
-40328.3% / -8379.8%
FY2021-FY2024
Trend
-217.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin changed -218% YoY in FY2024, a notable deviation from the 3-year average annual change of -80%.
Based on SEC 10-K filings.
-40328.3% in FY2024 with a 3-year CAGR of -28280.7%.
Declined from -8379.8% to -40328.3% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- -28280.7pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, operating margin decreased 217.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -40328.3% | -217.8% |
| FY2023 | -12688.1% | -51.4% |
| FY2022 | -8379.8% | +30.4% |
| FY2021 | -12047.5% | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026